By Ethan Covey
Ceftazidime-avibactam (C/A; Avycaz, Allergan) may be a viable, effective treatment alternative to ceftolozane-tazobactam (C/T; Zerbaxa, Merck) for patients with Pseudomonas aeruginosa infections, according to a study presented at the 2022 IDWeek conference, held in Washington, D.C.
“Novel beta-lactam/beta-lactamase inhibitors including C/T and C/A are first-line treatments for resistant Pseudomonas aeruginosa infections,” said Austin Golia, PharmD, an infectious